Revolutionary Results: AlzeCure’s NeuroRestore ACD856 Proven as Promising Alzheimer’s and Cognitive Disorder Treatment

AlzeCure Pharma AB (publ)(FN STO:ALZCUR), a pharmaceutical company dedicated to developing small molecule candidate drugs for diseases affecting the central nervous system, has released a new study published on NeuroRestore ACD856. This study reports promising preclinical results indicating a potential disease-modifying effect of ACD856 in Alzheimer’s disease and pain. This groundbreaking new study brings us one step closer to developing innovative treatments for these debilitating conditions.

The International Journal of Molecular Sciences has recently published an exciting article, entitled “Neuroprotective and Disease Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease”! written by a talented team of researchers, led by Pontus Forsell, Head of Research and Discovery.

The co-authors, Cristina Parrado-Fernandez, Sanja Juric, Maria Backlund, Märta Dahlström, Nather Madjid, Veronica Lidell, Azita Rasti, Johan Sandin and Gunnar Nordvall, aimed to explore the efficacy of this novel triazinetrione ACD856 in treating Alzheimer’s disease.

ACD856 is an innovative neurological drug candidate on the cutting-edge NeuroRestore platform designed to increase BDNF and NGF signaling. Through rigorous preclinical testing processes, ACD856 has been widely shown to display a host of positive effects – from promoting neurite outgrowth and protect against nerve damage caused by amyloid-beta buildup, to enhancing the synapses that facilitate the exchange of information between nerve cells. It is without a doubt that the impact of ACD856 is nothing short of remarkable.

We are delighted to report that the data presented in this article supports a strong evidence base indicating that ACD856 can potentially provide a strong line of defense against Alzheimer’s disease, both in terms of preventing its progression and treating its symptoms. In both in-vitro and in-vivo studies, ACD856 showed a significant protective effect against amyloid-beta neurotoxicity, and also boosted levels of the essential neurotrophin BDNF.

These exciting results could mean potential in the development of a powerful combination therapy of ACD856 and anti-amyloid antibodies, such as Leqembi (lecanemab), for Alzheimer’s sufferers. Our research and discovery team at AlzeCure Pharma is hopeful about the future of ACD856 in this fight.

Martin Jönsson, CEO of AlzeCure Pharma AB, expressed his excitement regarding the potential for neurotrophins to be used as novel treatments for various neurodegenerative diseases, such as Alzheimer’s, depression, and Parkinson’s. He further noted that the recent results with ACD856 significantly bolster the commercial potential of the project, thus paving the way for Phase II studies to be conducted.

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company pioneering the fight against severe diseases and conditions affecting the central nervous system like Alzheimer’s and pain. Listed on the Nasdaq First North Premier Growth Market, the company is utilizing three powerful research platforms—NeuroRestore®, Alzstatin® and Painless—to develop a host of innovative drug therapies that provide effective treatment options in areas where current options are limited.

NeuroRestore presents a unique and revolutionary approach to tackling neurodegenerative disorders such as Alzheimer’s, Traumatic Brain Injury, Sleep Apnea, and Parkinson’s Disease. With two symptomatic drug candidates running on the Alzstatin platform, treatments are not only symptom-targeting but are also preventative and disease-modifying.

Additionally, NeuroRestore’s research platform, Painless, is also researching treatments for neuropathic pain, as exemplified by drug candidate ACD440, and severe pain conditions via TrkA-NAM.

As part of its commitment to innovation and development, AlzeCure is investing in preclinical research and development, as well as a clinical phase, with the ultimate goal of providing quality outlicensing solutions to pharmaceutical companies.

About NeuroRestore

NeuroRestore has developed a revolutionary platform of symptom-relieving drug candidates to improve cognitive ability in a variety of diseases, such as Alzheimer’s Disease, sleep apnea, traumatic brain injury, and Parkinson’s disease. The platform stimulates several important signaling pathways in the brain, which leads to improved cognitive function.

Preclinical studies suggest NeuroRestore substances – referred to as Trk-PAMs – could improve communication between synapsis, and increase the survival rate of nerve cells, demonstrating both cognitive-enhancing and disease-modifying effects. The leading drug candidate in the platform, ACD856, has recently completed clinical phase I studies, showing positive results that could support further development of the program.

Alzheimer’s is a devastating illness that affects an estimated 45 million people across the globe. This figure is expected to rise due to the lack of preventive and disease-modifying treatments currently available and the fact that the main risk factors for developing Alzheimer’s are age and genetics.

Although the disease may manifest itself in people as young as 40, it is most commonly seen in seniors aged 65 and above. As the economic burden of Alzheimer’s is staggering – it is estimated that the global cost for dementia related diseases in 2018 was a massive 1,000billion USD – the call for new effective therapies is loud.

So far, the few drugs approved for their symptomatic effect can cause limiting side effects, hence a disease-modifying treatment that could significantly improve lives would be invaluable. Sweden, for instance, is home to 100,000 Alzheimer’s sufferers, with related healthcare costs totaling a claimed SEK 63 billion every year, which is more than what is spent on those with cancer and cardiovascular problems combined.

Leave a Comment